scholarly journals Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition

Cancer ◽  
2020 ◽  
Vol 126 (15) ◽  
pp. 3579-3592 ◽  
Author(s):  
Alicia M. Blessing ◽  
Janice M. Santiago‐O'Farrill ◽  
Weiqun Mao ◽  
Lan Pang ◽  
Jing Ning ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Anaplastic Lymphoma Kinase ◽  
Ovarian Cancer Cells ◽  
Kinase Inhibition ◽  
Anaplastic Lymphoma ◽  
Enhanced Sensitivity

Abstract 3313: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to Crizotinib

2017 ◽  
Author(s):  
Alicia M. Blessing ◽  
Yan Wang ◽  
Weiqun Mao ◽  
Lan Pang ◽  
Zhen Lu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Enhanced Sensitivity

Abstract 4263: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to ALK inhibition

2019 ◽  
Author(s):  
Alicia M. Blessing ◽  
Weiqun Mao ◽  
Lan Pang ◽  
Philip Rask ◽  
Zhen Lu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Enhanced Sensitivity

scholarly journals EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer

2020 ◽  
Vol 50 (12) ◽  
pp. 1470-1474
Author(s):  
Beina Hui ◽  
Jingping Zhang ◽  
Xiaobo Shi ◽  
Fangfang Xing ◽  
Yang W Shao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitor ◽  
Fusion Gene ◽  
Ovarian Cancer Cells ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Kinase Gene ◽  
Anaplastic Lymphoma Kinase Inhibitor ◽  
Anaplastic Lymphoma

Abstract Ovarian cancer is prone to recurrence and chemotherapy resistance. Ovarian tumours of some patients have been positive for anaplastic lymphoma kinase fusion gene expression (ALK+). Preclinical studies indicate that anaplastic lymphoma kinase inhibitor can suppress the growth of ovarian cancer cells and transplantation tumours. Here, we present a patient with metastatic ALK+ high-grade serous ovarian cancer that testing positive for EML4-ALK (microtubule-associated protein-like 4 gene, fused to the anaplastic lymphoma kinase gene), experienced dramatic benefit after administration of the anaplastic lymphoma kinase inhibitor alectinib. This is the first clinical evidence that treatment with alectinib may provide a personalized maximum benefit for patients with high-grade serous ovarian cancer who are positive for EML4-ALK.

scholarly journals Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition

2012 ◽  
Vol 132 (10) ◽  
pp. 2258-2269 ◽  
Author(s):  
Jing Hu ◽  
Holly Deng ◽  
Eileen A. Friedman
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Normal Cells ◽  
Kinase Inhibition

Abstract 4263: Autophagic ovarian cancer cells exhibit substantially enhanced sensitivity to ALK inhibition

2019 ◽  
Author(s):  
Alicia M. Blessing ◽  
Weiqun Mao ◽  
Lan Pang ◽  
Philip Rask ◽  
Zhen Lu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Enhanced Sensitivity

Cytotoxic effects of disulfiram and synergism with cisplatin on ovarian cancer cells in vitro

2018 ◽  
Author(s):  
F Guo ◽  
Z Yang ◽  
J Xu ◽  
J Sehouli ◽  
AE Albers ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Cytotoxic Effects
Sign in / Sign up

Export Citation Format

Share Document